Better Understanding and Recognition of the Disconnects, Experiences, and Needs of Patients with Irritable Bowel Syndrome with Constipation (BURDEN IBS-C) Study

Results of an Online Questionnaire

Eamonn M.M. Quigley, John Horn, Michele Kissous-Hunt, Robert A. Crozier, Lucinda A. Harris

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Introduction: The BURDEN IBS-C study was conducted to better understand the experiences, attitudes, and unmet needs of sufferers of irritable bowel syndrome with constipation (IBS-C) in comparison to the perceptions and challenges of healthcare providers (HCPs) who treat IBS-C patients. Methods: This was an author-developed, online questionnaire using KnowledgePanel® to survey individuals with IBS-C (N = 1311). HCPs participated in a complementary online questionnaire and were recruited separately (N = 331). The study was fielded from June 29, 2016, to January 30, 2017. Results: Most patients had used (86%) and/or were using (76%) over-the-counter treatments for their IBS-C, with 12% currently on prescription therapy. At the time this study was conducted, 66% and 63% were not satisfied/completely satisfied with over-the-counter or prescription treatment, respectively, citing inadequate efficacy (55%) and side effects (39%), most commonly diarrhea, as common reasons for dissatisfaction. IBS-C respondents most commonly reported feeling frustrated (43%) and stressed (28%) regarding IBS-C, though 39% were accepting of IBS-C as part of daily life. HCPs were aligned with patients in thinking that patients were frustrated (76%) and stressed (65%) but HCPs were less likely to recognize that patients had become accepting of their IBS-C (13%). Most HCPs (79%) were not satisfied/completely satisfied with the prescription treatments available at the time this study was conducted. Inadequate response rates to current therapies (55%) and treatment adherence/compliance issues (58%) were the most frequent challenges encountered by HCPs. IBS-C respondents reported that their symptoms impacted productivity and personal activity, on average, 4 and 3 days/month, respectively. Conclusion: These results suggest that current management pathways may not be adequately addressing the symptoms and needs of individuals with IBS-C, most notably side effects and lack of efficacy. Patients and HCPs expressed dissatisfaction with over-the-counter and prescription treatments available at the time this study was conducted. Additional treatment options and improved dialogue would be beneficial to HCPs and patients. Funding: Synergy Pharmaceuticals Inc.

Original languageEnglish (US)
Pages (from-to)1-14
Number of pages14
JournalAdvances in Therapy
DOIs
StateAccepted/In press - Jun 26 2018

Fingerprint

Irritable Bowel Syndrome
Constipation
Health Personnel
Time and Motion Studies
Prescriptions
Therapeutics
Recognition (Psychology)
Surveys and Questionnaires
Compliance
Diarrhea
Emotions
Efficiency

Keywords

  • Gastroenterology
  • Irritable bowel syndrome with constipation
  • Quality of life
  • Survey

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Better Understanding and Recognition of the Disconnects, Experiences, and Needs of Patients with Irritable Bowel Syndrome with Constipation (BURDEN IBS-C) Study : Results of an Online Questionnaire. / Quigley, Eamonn M.M.; Horn, John; Kissous-Hunt, Michele; Crozier, Robert A.; Harris, Lucinda A.

In: Advances in Therapy, 26.06.2018, p. 1-14.

Research output: Contribution to journalArticle

@article{2af72e900ade43cd8c3e948288c9ca4c,
title = "Better Understanding and Recognition of the Disconnects, Experiences, and Needs of Patients with Irritable Bowel Syndrome with Constipation (BURDEN IBS-C) Study: Results of an Online Questionnaire",
abstract = "Introduction: The BURDEN IBS-C study was conducted to better understand the experiences, attitudes, and unmet needs of sufferers of irritable bowel syndrome with constipation (IBS-C) in comparison to the perceptions and challenges of healthcare providers (HCPs) who treat IBS-C patients. Methods: This was an author-developed, online questionnaire using KnowledgePanel{\circledR} to survey individuals with IBS-C (N = 1311). HCPs participated in a complementary online questionnaire and were recruited separately (N = 331). The study was fielded from June 29, 2016, to January 30, 2017. Results: Most patients had used (86{\%}) and/or were using (76{\%}) over-the-counter treatments for their IBS-C, with 12{\%} currently on prescription therapy. At the time this study was conducted, 66{\%} and 63{\%} were not satisfied/completely satisfied with over-the-counter or prescription treatment, respectively, citing inadequate efficacy (55{\%}) and side effects (39{\%}), most commonly diarrhea, as common reasons for dissatisfaction. IBS-C respondents most commonly reported feeling frustrated (43{\%}) and stressed (28{\%}) regarding IBS-C, though 39{\%} were accepting of IBS-C as part of daily life. HCPs were aligned with patients in thinking that patients were frustrated (76{\%}) and stressed (65{\%}) but HCPs were less likely to recognize that patients had become accepting of their IBS-C (13{\%}). Most HCPs (79{\%}) were not satisfied/completely satisfied with the prescription treatments available at the time this study was conducted. Inadequate response rates to current therapies (55{\%}) and treatment adherence/compliance issues (58{\%}) were the most frequent challenges encountered by HCPs. IBS-C respondents reported that their symptoms impacted productivity and personal activity, on average, 4 and 3 days/month, respectively. Conclusion: These results suggest that current management pathways may not be adequately addressing the symptoms and needs of individuals with IBS-C, most notably side effects and lack of efficacy. Patients and HCPs expressed dissatisfaction with over-the-counter and prescription treatments available at the time this study was conducted. Additional treatment options and improved dialogue would be beneficial to HCPs and patients. Funding: Synergy Pharmaceuticals Inc.",
keywords = "Gastroenterology, Irritable bowel syndrome with constipation, Quality of life, Survey",
author = "Quigley, {Eamonn M.M.} and John Horn and Michele Kissous-Hunt and Crozier, {Robert A.} and Harris, {Lucinda A.}",
year = "2018",
month = "6",
day = "26",
doi = "10.1007/s12325-018-0733-x",
language = "English (US)",
pages = "1--14",
journal = "Advances in Therapy",
issn = "0741-238X",
publisher = "Health Communications Inc.",

}

TY - JOUR

T1 - Better Understanding and Recognition of the Disconnects, Experiences, and Needs of Patients with Irritable Bowel Syndrome with Constipation (BURDEN IBS-C) Study

T2 - Results of an Online Questionnaire

AU - Quigley, Eamonn M.M.

AU - Horn, John

AU - Kissous-Hunt, Michele

AU - Crozier, Robert A.

AU - Harris, Lucinda A.

PY - 2018/6/26

Y1 - 2018/6/26

N2 - Introduction: The BURDEN IBS-C study was conducted to better understand the experiences, attitudes, and unmet needs of sufferers of irritable bowel syndrome with constipation (IBS-C) in comparison to the perceptions and challenges of healthcare providers (HCPs) who treat IBS-C patients. Methods: This was an author-developed, online questionnaire using KnowledgePanel® to survey individuals with IBS-C (N = 1311). HCPs participated in a complementary online questionnaire and were recruited separately (N = 331). The study was fielded from June 29, 2016, to January 30, 2017. Results: Most patients had used (86%) and/or were using (76%) over-the-counter treatments for their IBS-C, with 12% currently on prescription therapy. At the time this study was conducted, 66% and 63% were not satisfied/completely satisfied with over-the-counter or prescription treatment, respectively, citing inadequate efficacy (55%) and side effects (39%), most commonly diarrhea, as common reasons for dissatisfaction. IBS-C respondents most commonly reported feeling frustrated (43%) and stressed (28%) regarding IBS-C, though 39% were accepting of IBS-C as part of daily life. HCPs were aligned with patients in thinking that patients were frustrated (76%) and stressed (65%) but HCPs were less likely to recognize that patients had become accepting of their IBS-C (13%). Most HCPs (79%) were not satisfied/completely satisfied with the prescription treatments available at the time this study was conducted. Inadequate response rates to current therapies (55%) and treatment adherence/compliance issues (58%) were the most frequent challenges encountered by HCPs. IBS-C respondents reported that their symptoms impacted productivity and personal activity, on average, 4 and 3 days/month, respectively. Conclusion: These results suggest that current management pathways may not be adequately addressing the symptoms and needs of individuals with IBS-C, most notably side effects and lack of efficacy. Patients and HCPs expressed dissatisfaction with over-the-counter and prescription treatments available at the time this study was conducted. Additional treatment options and improved dialogue would be beneficial to HCPs and patients. Funding: Synergy Pharmaceuticals Inc.

AB - Introduction: The BURDEN IBS-C study was conducted to better understand the experiences, attitudes, and unmet needs of sufferers of irritable bowel syndrome with constipation (IBS-C) in comparison to the perceptions and challenges of healthcare providers (HCPs) who treat IBS-C patients. Methods: This was an author-developed, online questionnaire using KnowledgePanel® to survey individuals with IBS-C (N = 1311). HCPs participated in a complementary online questionnaire and were recruited separately (N = 331). The study was fielded from June 29, 2016, to January 30, 2017. Results: Most patients had used (86%) and/or were using (76%) over-the-counter treatments for their IBS-C, with 12% currently on prescription therapy. At the time this study was conducted, 66% and 63% were not satisfied/completely satisfied with over-the-counter or prescription treatment, respectively, citing inadequate efficacy (55%) and side effects (39%), most commonly diarrhea, as common reasons for dissatisfaction. IBS-C respondents most commonly reported feeling frustrated (43%) and stressed (28%) regarding IBS-C, though 39% were accepting of IBS-C as part of daily life. HCPs were aligned with patients in thinking that patients were frustrated (76%) and stressed (65%) but HCPs were less likely to recognize that patients had become accepting of their IBS-C (13%). Most HCPs (79%) were not satisfied/completely satisfied with the prescription treatments available at the time this study was conducted. Inadequate response rates to current therapies (55%) and treatment adherence/compliance issues (58%) were the most frequent challenges encountered by HCPs. IBS-C respondents reported that their symptoms impacted productivity and personal activity, on average, 4 and 3 days/month, respectively. Conclusion: These results suggest that current management pathways may not be adequately addressing the symptoms and needs of individuals with IBS-C, most notably side effects and lack of efficacy. Patients and HCPs expressed dissatisfaction with over-the-counter and prescription treatments available at the time this study was conducted. Additional treatment options and improved dialogue would be beneficial to HCPs and patients. Funding: Synergy Pharmaceuticals Inc.

KW - Gastroenterology

KW - Irritable bowel syndrome with constipation

KW - Quality of life

KW - Survey

UR - http://www.scopus.com/inward/record.url?scp=85049085649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049085649&partnerID=8YFLogxK

U2 - 10.1007/s12325-018-0733-x

DO - 10.1007/s12325-018-0733-x

M3 - Article

SP - 1

EP - 14

JO - Advances in Therapy

JF - Advances in Therapy

SN - 0741-238X

ER -